Saudi Arabia Wins WSIS Prize 2021    Saudi Stock Exchange Main Index Ends Trading Higher at 10,423.51 Points    Jordan Records 1,174 New COVID-19 Cases    Bahraini Foreign Minister Receives Phone Call from His US Counterpart    Al-Asoumi commends Saudi Arabia's support for Sudan    Dr. Al-Sheikh affirms Saudi Arabia's commitment to achieve sustainable development    EAD continues to implement plans to protect Al Wathba Fossil Dunes    India logs record number of Covid deaths as caseload hits 25 million    Indian Navy hunts for 80 missing at sea after devastating cyclone    Russia Reports 8,183 New COVID-19 Cases, 364 Deaths    OIC's IPHRC holds Israel fully accountable for random killing of innocent Palestinians    Museums Commission to host a virtual concert on International Museum Day    Saudi Press: Social Responsibility Leads Next Phase of Controlling Pandemic    Prosthetics Center in Aden Continues to Provide Services with KSRelief's Support    Weather Forecast for Tuesday    Biden expresses 'support' for Gaza ceasefire in call with Netanyahu    King Salman reviews bilateral ties with Bahraini king in phone call    US secretary of state, UAE foreign minister review developments in Israel, Palestine Blinken speaks to EU's Borrell to coordinate efforts to ease Mideast tensions    Museums Commission to host a virtual concert on International Museum Day    Working for 55 hours or more in a week health hazard: WHO Long working hours killing 745,000 people a year, study finds    FDIs into UAE grow by 44.2 percent in 2020    First Flight Flown Form Hail International Airport Heading to Cairo    Al-Attiyah guides Toyota to victory in Andalucia Rally    Saudi Arabia Ranks 5th Worldwide, in Terms of Mobile Internet's Speed    Madinah airport ready for resumption of international flights    STA brings the best of Saudi to Arabian Travel Market 2021    Ensure digital technologies are 'a force for good' — Guterres    Gardening is 'political' says Irish celebrity horticulturist    Only 'coronavirus immune' citizens over 18 years of age can travel to Bahrain    Tyson Fury confirms date for long-awaited fight against Anthony Joshua    Saudi Arabia to Take Part in the World Hypertension Day    Diego Maradona    Remarkable collection of Syrian art transcends horrors of war: Arte Arta Gallery    Champions League final 2021 moved from Istanbul to Porto's Estádio do Dragão    Tawakkalna Launches Registration Service to Donate Organs on its Website    From whom do we take Shariah? How do we get legitimacy?    Sheikh Salman Al Khalifa: Saudi Football Association is distinguished and professional    Saudi Rower Hussain Alireza sets for 2021 Tokyo Olympics qualifiers    Asian Handball Championships' Draw to Take Place in Jeddah on Saturday    President of Union of Arab Football Associations Meets with Heads of FIFA, AFC and CAF    Business Lady Led Saudi World Competitiveness Edge, in Banana Planting    Welcome to beautiful Ramadan customs    Vaccination does not invalidate fasting, says UAE Fatwa Council    It is high time to correct wrong concepts about women's status    Council of Senior Scholars: Muslim Brothers' Group Don't Represent Method of Islam, rather only Follows its Partisan Objectives, Violating our Graceful Religion    Eid Al-Adha Prayer Performed at the Grand Holy Mosque    Pilgrims Perform Dhuhr and Asr Prayers in Arafat Holy Site    Senior Scholars Council Issues Decision No. 246 Regarding Attendance of Friday Prayer and Prayers at Mosques in a Case of Spread of Epidemic or Fear of its Spread    







Thank you for reporting!
This image will be automatically disabled when it gets reported by several people.





Russia's Sputnik V vaccine 91.6% effective in late-stage trial
Published in The Saudi Gazette on 02 - 02 - 2021

After criticism last year for an early rollout, Russia's Sputnik V vaccine is 91.6 percent effective against symptomatic COVID-19 and 100 percent effective against severe and moderate disease, according to an interim analysis of the vaccine's Phase 3 trial results.
The preliminary findings were published in The Lancet on Tuesday and are based on data gathered from 19,866 participants, of which around three-quarters (14,964) received two doses of the vaccine and a quarter (4,902) were given a placebo.
Sixteen cases of symptomatic COVID-19 were confirmed in the vaccine group 21 days after participants received the first vaccine dose. Sixty two cases were found in the placebo group — equating to an efficacy of 91.6 percent.
The trial included 2,144 people over the age of 60 and a sub-analysis conducted on this group revealed the vaccine was well tolerated and had a similar efficacy of 91.8 percent.
The team also analyzed the efficacy of the vaccine against severe and moderate COVID-19 disease and 21 days after the first dose no severe or moderate cases were reported in the vaccinated group, while 20 were reported in the placebo group.
Serious adverse events associated with vaccination were also rare —less than 0.2 percent in people who received the vaccine. The majority of side-effects that were reported were mild side, such as pain at the injection site, flu like symptoms and low energy levels, according to the study.
The analysis includes only symptomatic cases of COVID-19, however, and the authors note more research is needed to understand the vaccine's efficacy against asymptomatic COVID-19-19, transmission and how long protection may last.
The majority of participants in the trial were also white so further research is needed to confirm the results across other ethic groups. The trial is also ongoing and is aiming to include a total of 40,000 participants.
Dr. Inna V Dolzhikova, co-lead author of the study, said the analysis suggested the vaccine had "high efficacy, immunogenicity, and a good tolerability profile in participants aged 18 years or older."
Dolzhikova works at Russia's Gamaleya National Research Centre for Epidemiology and Microbiology, which developed the vaccine.
The people in the trial were given PCR Covid-19 tests when they received the second shot. They took a further test if they reported symptoms of respiratory infection.
The Sputnik V vaccine is a two-dose adenoviral vector vaccine using two different adenoviruses for each dose, with doses administered 21 days apart. With this type of vaccine, an adenovirus is altered so that it can deliver a piece of genetic material from the virus that causes COVID-19 into the body and get cells to express the spike induce found on the virus and induce an immune response. It's an approach similar to the vaccines developed by AstraZeneca and Johnson & Johnson.
The authors say that using a different adenovirus vector for the booster vaccination may help create a more powerful immune response.
One advantage of adenoviral vaccines is that they do not need to be stored and transported in extremely cold temperatures, scientists say. Sputnik V only needs to be refrigerated and costs $10 per dose, according to Russian Direct Investment Fund, which funded vaccine production and is responsible for selling it globally.
"This is a useful addition to the published data on COVID-19 vaccine effectiveness," Dr. Julian Tang, clinical virologist at the University of Leicester.
But he highlighted that "median follow up was 48 days from the first dose, so the study cannot assess the full duration of protection."
The vaccine's production has been funded by the Russian Direct Investment Fund (RDIF), which is also responsible for selling it globally.
The vaccine is already approved in Russia, Belarus, Serbia, Argentina, Bolivia, Algeria, Venezuela, Paraguay, Turkmenistan, Hungary, UAE, Iran, Guinea, Tunisia, Armenia and the Palestinian territories. Sputnik V has so far been administered to more than 2 million people worldwide.
Russia drew criticism from scientific circles last year when it approved Sputnik V for public use in August — before the crucial Phase 3 trials had been completed.
"Despite the earlier misgivings about the way this Russian Sputnik V vaccine was rolled out more widely — ahead of sufficient Phase 3 trial data — this approach has been justified to some extent now," Tang said.
"The vaccine trial results are coming thick and fast as high infection rates in areas where Phase 3 clinical trials provide increasing amounts of data that together encourages us to believe that vaccines will soon be able to drive down the human cost of Covid-19," added Alexander Edwards, associate professor in Biomedical Technology at the Reading School of Pharmacy, University of Reading.
"Manufacturing may remain a bottleneck for months to come, so the more vaccines available, the better for global health," he said. — Courtesy CNN


Clic here to read the story from its source.